Global Rx dermatology topical drug delivery market is expected to reach USD 40,646.26 million by 2026 from USD 29,475.18 million in 2018, growing at a CAGR of 4.2% in the forecast period of 2019 to 2026. The years considered for study are as mentioned below. Access Full Report at https://databridgemarketresearch.com/reports/global-rx-dermatology-topical-drug-delivery-market Topical drug administration can be done in the body through ophthalmic, rectal, vaginal and skin as topical routes. In dermatology sector, skin plays a major role for the administration of topical drug for the treatment of skin disease in patients. The topical preparations are applied on the skin for surface, local or systemic effects. The topical formulations include therapeutically active ingredients which help in treating the skin diseases in patients. Prominent factors driving the growth of this market consist of increasing prevalence of skin disease or condition, rising aging population, growth in topical drug delivery, increasing research and development of new dermatological drugs, new product launches. With the increasing prevalence of chronic diseases the demand for development and innovation of drugs is increasing. This growing demand has provided an opportunity for the pharmaceutical companies to focus on introducing various products. For instance, according to American Academy of Dermatology, 50.0 million of Americans annually gets affected with acne. It is common diseases which can be treated easily and hence topical drugs are useful in treating such diseases and hence it demand is increasing. The market has witnessed developments in terms of merger and acquisitions or product launches to enhance the product portfolio to meet the rising demand of innovative strains. For instance, In April 2019, LEO Pharma A/S announced that they have entered in partnership with Elektrofi (U.S.) with the aim of achieving improvements in drug delivery within dermatology. The aim behind this partnership was to provide new, more convenient solutions for drug delivery in market for the patients. GlaxoSmithKline plc dominated the global Rx dermatology topical drug delivery market and accounts for the highest market share in 2018 which is followed by Pfizer Inc., Galderma Laboratories, L.P., LEO Pharma A/S, Bausch Health Companies Inc., ALLERGAN. Some of the other major players operating in the market are Hisamitsu Pharmaceutical Co., Inc., Bayer AG, 3M, The Lubrizol Corporation, Cipla Inc., Kaken Pharmaceutical Co., Ltd. and others. GlaxoSmithKline plc. The company was established in 2000, headquarter in Brentford, U.K. The company is focused in the innovation, development, manufacturing and marketing of vaccines, pharmaceutical products, health-related consumer products and over-the-counter medicines. The main business segments of the company are pharmaceuticals, consumer health, vaccines. In 2018, company’s pharmaceuticals segment generated around 56.03% of revenue followed by consumer health with 24.85% and vaccines with 19.12%. Pharmaceuticals sales were declined over all. But the categories in this segment like Respiratory and HIV got with driven primarily by the growth in HIV sales and the new Respiratory products, Nucala and the Ellipta portfolio with 9.0% and 1.0% respectively. In 2018, the company generated USD 41,315.55 million revenue from its business and has around 95,490 employees. The company has its global network in Africa, Asia & the Middle East, Australia, Europe, North America, South & Central America. The company has its subsidiaries such as Allen Pharmazeutika Gesellschaft m.b.H. (Austria), Tesaro, Inc. (U.S.), ViiV Healthcare Limited (U.K.), Stiefel Laboratories, Inc. (U.K.), among others. Pfizer Inc. The company was founded in 1849, headquarters in New York, U.S. The company is engaged in the discovery, development, manufacturing and sells of healthcare products worldwide. The company has its business segment and they are IH (Innovative Health Segment) and EH (Essential Health Segment). The IH (Innovative Health Segment) segment’s revenue got declined in 2018 from 2017 with 6.38% due to increasing demand for the products and launches in market. The company has generated revenue in 2018 was around USD 33,426.00 million and employees around 92,400. In May 2016, Pfizer Inc. acquired Anacor Pharmaceuticals Inc ANAC.O with the huge amount of about USD 5.2 billion. The acquisition was mainly done to increase their product portfolio with addition an eczema gel to its portfolio. The acquisition gave an opportunity to Pfizer Inc. to address a significant unmet medical need for a large patient population. The company has its global network in North America, South America, Europe, Asia-Pacific, Middle East and Africa. The company has its subsidiaries such as Warner-Lambert Company LLC (U.S.), Pfizer Enterprises SARL (Luxembourg), Pfizer Luxembourg SARL (Luxembourg), Pfizer Investment Co. Ltd. (China), Wyeth Lederle S.p.A. (Italy) among others. Galderma Laboratories, L.P. The Galderma Laboratories, L.P. was founded in 1981 and headquartered in Taxes, U.S. The company is engaged in research and development of new dermatological solutions and aesthetic and corrective products. The company has its product categories and they are medical solutions, aesthetics, consumer solutions. The company has global presence in Asia-Pacific, Europe, Middle East, Africa, Latin America, North America. In March 2017, Galderma Laboratories, L.P., makers of Cetaphil brand launched seven new facial skincare products. With this launch of the products Cetaphil portfolio of the company has increased. The company has now broad range of specialized solutions for the patients with skin concerns, including hydration and others.
